Tranexamic%252520acid

# Tranexamic Acid ## Overview Tranexamic acid (TXA) is a synthetic antifibrinolytic agent that competitively inhibits the activation of plasminogen to plasmin, thereby preventing the breakdown of fibrin clots. ## Primary Indications * **Hemorrhage:** Treatment or prevention of excessive bleeding in trauma, surgery, or obstetric contexts (postpartum hemorrhage). * **Menorrhagia:** Treatment of cyclic heavy menstrual bleeding. * **Hereditary Angioedema:** Prophylaxis of acute attacks. * **Epistaxis/Dental:** Localized management of minor bleeding (often as a mouthwash). ## Adult Dosing * **Trauma/Acute Hemorrhage:** 1 g IV loading dose over 10 minutes, followed by 1 g IV infusion over 8 hours. Administer within 3 hours of injury. * **Postpartum Hemorrhage:** 1 g IV over 10 minutes. May repeat 1 g IV once if bleeding continues after 30 minutes or recurs within 24 hours. * **Heavy Menstrual Bleeding:** 1.3 g orally three times daily for up to 5 days during menstruation. * **Surgical Prophylaxis/Local:** Highly variable based on institution; ranges from 10–20 mg/kg IV pre-operatively to topical application (e.g., 500 mg in 10 mL sterile water for mouthwash). ## Pediatric Dosing * **Trauma:** 15–20 mg/kg IV loading dose (max 1 g), followed by 2 mg/kg/hour infusion for up to 8 hours. *Verify against local institutional trauma protocol.* * **Hereditary Angioedema:** 10 mg/kg orally three times daily (max 1.5 g/day). ## Dose Adjustments * **Renal Impairment:** Requires reduction in patients with creatinine clearance <50 mL/min. * CrCl 30–50 mL/min: Reduce dose by 50% or increase dosing interval. * CrCl <30 mL/min: Use with caution; further reduction or avoid. * **Hepatic Impairment:** No specific adjustment required. ## Contraindications * Active intravascular clotting (thromboembolic disease). * History of deep vein thrombosis (DVT) or pulmonary embolism (PE). * Color vision disturbances (may indicate underlying retinal toxicity). * Subarachnoid hemorrhage (theoretical risk of cerebral vasospasm/ischemia). ## Adverse Effects * **Gastrointestinal:** Nausea, vomiting, diarrhea (more common with oral dosing). * **Neurological:** Seizures (notably with high doses, rapid injection, or in patients with history of epilepsy). * **Vascular:** Hypotension (if infused too rapidly); risk of thromboembolic events. * **Visual:** Changes in color vision or retinal ischemia. ## Key Drug Interactions * **Estrogens/Oral Contraceptives:** Concomitant use significantly increases the risk of thrombosis. * **Factor IX complex/Prothrombin complex concentrates:** Increased risk of thrombosis if used concurrently with antifibrinolytics. ## Monitoring * Monitor hemoglobin/hematocrit and signs of ongoing bleeding. * Monitor for clinical signs of thrombosis (DVT, PE). * Monitor neurological status (seizure precautions in high-dose settings). * Monitor ophthalmic symptoms if therapy is prolonged. ## Clinical Pearls * **Speed Matters:** In trauma, efficacy is inversely related to time from injury. Treatment beyond 3 hours may result in increased mortality. * **Speed Kills:** Rapid IV pushing is associated with profound, transient hypotension; always dilute and infuse over at least 10 minutes. * **Avoid "Over-Anticoagulation":** Ensure concurrent anticoagulants are reviewed and held if appropriate. * **Seizure Risk:** The risk of seizures is highest in patients receiving high doses during cardiac surgery or those with underlying CNS disorders. *** *Disclaimer: This information is for educational purposes only. Clinical guidelines and dosing protocols vary by institution and patient population. Always verify prescribing information, renal function, and drug compatibility via current medical references or institutional pharmacy staff before administration.*